Biochips for better cancer therapy

Cancer is the second leading cause of disease-related death in the United States, and may overtake heart disease without aggressive new therapies. One promising area of cancer treatment is photodynamic therapy (PDT), which combines the agents of a photosensitive drug, light, and oxygen to attack cancerous tumors and lesions locally in the targeted region of the body by selective optical illumination.

Research being conducted by Prof. Euisik Yoon's group aims to dramatically accelerate progress in PDT. And it is being accomplished through a lab-on-a-chip measuring about the size of a quarter. At the heart of this biochip is a 5x5mm testing area that will test the interaction of the drug, light, and oxygen simultaneously, generating results in a fraction of the time of current testing practices.

"In cancer research doctors are always looking for better drugs," explained Dr. Xia Lou, a postdoctoral fellow in Prof. Yoon's group. "But there has always been a lack in the ability to efficiently test . Researchers are also hoping to get more reliable test results than is the norm. We are providing more precise drug test conditions to insure that the results we are getting will more closely match the actual results from ."

"PDT is a fairly complicated therapy because it requires light, oxygen and the drug, all three of which need to be carefully controlled," said Dr. Lou. "With chemotherapy, for example, you only control how much of the drug is used."

Biochips for better cancer therapy
The central testing area of this biochip is 5mm2. The inside structure is comprised of 3 layers, each testing a key element of the therapy: drug, oxygen, and light.

Photodynamic therapy uses a unique type of drug, called a photosensitizer, that generates high energy oxygen when activated by light, in this case an LED laser. The oxygen reaction destroys cells locally only in the immediate surrounding area, which in this case is the tumor, without damaging other healthy cells in the rest of the body. PDT may also prompt the patient's immune system to attack the tumor, whereas without treatment it will likely ignore it.

There are two primary challenges in PDT today. One is determining the best treatment plan for the patient, and the other is testing the efficacy of new and existing drugs. For example, the location of a tumor in the body will determine the amount of light needed to excite the drug, and will impact the amount of drug that is administered. Also, when testing new drugs, it is again important to know the amount of light needed to excite the reaction, and the strength of the reaction. This adds a high level of complexity compared to conventional drug testing that only tests one component, the itself.

Biochips for better cancer therapy
This 3D plot, generated from the biochip’s test results of actual cancer cells, tracks the simultaneous interactions of drug, oxygen, and light.

Current PDT testing methods might take more than 24 hours to acquire just 10 data points. "With our device," said Dr. Lou, "we can finish the testing in 1 hour and have 1,000 data points. The result is a very comprehensive understanding of how the 3 elements need to be manipulated for maximum effect in an individual patient."

More information: "A high-throughput photodynamic therapy screening platform with on-chip control of multiple microenvironmental factors." Xia Lou,et al. Lab Chip, 2014,14, 892-901. DOI: 10.1039/C3LC51077H

add to favorites email to friend print save as pdf

Related Stories

Light dynamics for cancer treatment

May 03, 2012

Research is delving into refinement of a revolutionary cancer treatment, photodynamic therapy (PDT). Using light, reactive oxygen and photosensitisers linked to specially designed antibodies, scientists are on the threshold ...

New targeted approach to light-activated cancer drugs

Nov 08, 2007

Combining light-activated cancer drugs with tumour-seeking antibodies could provide a more effective way of treating many cancers, according to new research published in advance online in the International Journal of Cancer.

COXEN model picks the best drug for ovarian cancer

Feb 18, 2014

There are three common drugs for advanced ovarian cancer: paclitaxel, cyclophosphamide, and topotecan. Like a shell game, if you pick the right drug a patient is likely to respond. And, unfortunately, picking the wrong drug ...

Recommended for you

How a common antacid could lead to cheaper anti-cancer drugs

12 hours ago

A popular indigestion medication can increase survival in colorectal cancer, according to research published in ecancermedicalscience. But in fact, scientists have studied this for years - and a group of cancer advocates want t ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.